Peptides for RA Relief?

KLOW is a premixed blend of GHK-Cu, BPC-157, TB4, and KPV. It really helps me with inflammation and healing. It's usually sold in 80mg vials. I mix a vial with 3mL of BAC and take 10 units per day. That gives me about 2.75mg daily for a month. I don't worry about overfill since a higher dose is fine. One place has single vials for around $41 if you want to try it without buying a full kit.
 
I've been reading about Melanotan 2 (MT2) and PT-141 (Bremelanotide). PT-141 was actually developed from MT2! I'm mainly interested in the libido benefits of PT-141. Has anyone here tried it for that purpose?
 
Sunny_Babe said:
I've been reading about Melanotan 2 (MT2) and PT-141 (Bremelanotide). PT-141 was actually developed from MT2! I'm mainly interested in the libido benefits of PT-141. Has anyone here tried it for that purpose?
Click to expand...

PT-141 can be a HUGE help for those who don't respond to certain ED pills. It works differently by increasing sexual desire through the central nervous system, rather than affecting blood flow like those other meds.
 
Has anyone looked into Beta Thymosins, especially TB-500, for RA? I saw a post about Carl Lanore using it for injuries and joint pain. I'm a little concerned about some studies linking it to cancer though. Has anyone else heard about this?
 
Thanks, Dog_Beer, for bringing that possible link to cancer with TB-500 to my attention. I think I will steer clear of that one! I might try the PEA that Ozempic_Oracle mentioned though. It's good to know there are some clinical studies backing it.
 
me and my wife switched from name brand 5mg straight to grey 5mg, no real difference except the price 😉 grey tends to be slightly more potent, vials often run 31-36mg when labeled 30mg.
 
The glucose-spiking trade-off with RA treatment is a real constraint. GLP-1s have documented secondary anti-inflammatory effects - some RA patients report benefit alongside primary treatment without the glucose cost.
 
The RA improvement alongside tirz tracks - GLP-1 reduces systemic inflammation, which lightens joint load before any specific peptide protocol. BPC-157 and KPV are the ones with the most direct overlap with RA inflammatory pathways. Worth asking those doctors specifically about that stack.
 
Patellar tendonitis and tennis elbow respond to both approaches - local near-site has more anecdotal support than systemic alone for joint injuries. Most people run systemic plus a low-volume pin at 1-2cm from the site for local concentration.
 
MS and peptide research is more developed than most conditions - BPC-157 for anti-inflammatory support and low dose naltrexone have the most user-documented interest in autoimmune neurological conditions. Starting with those rather than a full stack is the practical approach.
 
The steroid hesitation for long-term inflammation management is valid - glucocorticoids work against the metabolic improvements GLP-1 compounds achieve. For the disc case, structural fix first then peptides for recovery makes more sense than using peptides as the primary tool for structural damage.
 
the rheumatologist seeing consistent improvement across multiple patients is the kind of clinical observation that carries real weight - it is not a controlled study but a pattern across enough cases with different baselines to suggest the mechanism is real. the GLP-1 anti-inflammatory pathway affecting joint symptoms makes mechanistic sense; the same inflammatory cascade that drives metabolic syndrome also contributes to autoimmune joint inflammation
 
You must log in or register to reply here.
Back
Top